18 The authors noted that although multiple observational studies demonstrated fewer alcohol-related adverse events and a reduction in alcohol use with GLP-1 receptor agonists relative to placebo, there is less high-quality evidence supporting these agents for AUD at this time
Active Ingredient Retatrutide 120mg: A multi-receptor agonist being studied for chronic weight management and metabolic health
Semaglutide Weight loss trials Semaglutide Treatment Effect in People with obesity (STEP) studies had no upper limit in age [92,93,94,95]
Bibcode:1993BBRC..196..141G
2024, Wadden, Thomas A., et al
Shortages aside, many insurers still wont pay for GLP-1 agonists unless the patient has been diagnosed with diabetes or cardiovascular disease